Weight Loss Drug Maker Sinks 25% After New Safety Data Spooks Investors
Zealand Pharma's shares tumbled up to 26% after late‑stage trial data showed 19% of participants discontinued survodutide due to gastrointestinal side effects, far higher than the 2.9% on placebo. While the drug met its primary efficacy endpoints, the high dropout and vomiting rates raise doubts about its commercial viability against rivals tirzepatide and semaglutide. The sell‑off adds to a near‑50% year‑to‑date decline, following a previous worst‑day loss from a separate anti‑obesity trial.
‘Buying Stuff Like It’s Going Out of Fashion’: Biotech M&A on Track for Best Year Since Pre-Covid
Global biopharma mergers and acquisitions have surged in 2026, reaching $106 billion across 201 deals and putting the sector on track for a $250 billion‑plus year—the strongest since the 2019 pre‑COVID peak. The acceleration is driven by looming patent cliffs, buoyant public...
Amazon's Top Health Exec Is Stepping Down, Will Be Replaced by Amwell Co-Founder
Amazon announced that senior vice president Neil Lindsay will step down as head of Amazon Health Services on July 1, making way for Dr. Roy Schoenberg, a co‑founder of telemedicine firm Amwell. Lindsay, who has overseen Amazon Pharmacy, the One Medical acquisition...
Healthy Returns: Trump Officials Hit California with Medicaid Funding Freeze and Threaten Other States
The Trump administration announced a $1.3 billion freeze on Medicaid payments to California, warning it will suspend federal funding to any state that does not intensify fraud prosecutions. The action focuses on California’s In‑Home Supportive Services (IHSS) program, which has expanded...
Eli Lilly Accuses Church Bishops, Businessmen of Fraud in Trulicity Drug Rebate Scheme
Eli Lilly has filed a civil lawsuit in Miami accusing a Florida mail‑order pharmacy, DrugPlace, and a Tennessee‑based organization linked to the Church of God in Christ of running a six‑year scheme that siphoned more than $200 million in rebates on its...
Jim Cramer Says Today’s Market Is Punishing Stocks Harder than 1999
CNBC host Jim Cramer warned that today’s equity market is penalizing underperforming stocks more severely than during the 1999 dot‑com bubble. While the S&P 500 and Nasdaq posted fresh record closes, gains are concentrated in artificial‑intelligence and data‑center names, leaving a...
FDA Commissioner Defends Agency's Drug Approval Decisions After Wave of Backlash
FDA Commissioner Marty Makary faced intense media and political backlash after the agency rejected Replimune’s melanoma drug candidate. In a CNBC interview, Makary emphasized that three independent FDA panels reached the same safety conclusion and rejected accusations of bias toward...
Here's Our Monthly Update on All 31 Portfolio Stocks, Including 3 on the Buy List
The CNBC Investing Club’s April meeting reviewed all 31 stocks in Jim Cramer’s portfolio, noting a market rebound after the S&P 500 hit a record high. Cramer and Jeff Marks highlighted three new buy recommendations while reassessing positions across tech, industrials,...
A Mom and Tech Entrepreneur Building AI Advocate for Rare-Disease Families Like Hers
Citizen Health, founded by tech entrepreneurs Farid Vij and Nasha Fitter, has launched an AI‑powered "AI advocate" to help rare‑disease families manage appointments, insurance appeals, and clinical‑trial connections. The platform, backed by $44 million in venture capital—including a $30 million Series A—now supports...
CNBC Cures: A Father and a Doctor on How Raising a Child with Angelman Syndrome Changed Him
Dr. Joseph D’Orazio, an emergency physician, recounts how his son Gabe’s 2018 Angelman syndrome diagnosis transformed his family’s daily life and his own practice. The rare genetic disorder forced the family to restructure work schedules, manage relentless sleep disruption, and...
Stocks Soar on Hopes of Iran War Resolution — Plus, Lilly Takes a Big Swing in Sleep Disorders
U.S. equities surged as the S&P 500 jumped more than 2% on emerging signs that Iran may be moving toward a cease‑fire, buoyed by unconfirmed diplomatic overtures and a Trump statement supporting de‑escalation. Oil prices eased modestly, with WTI crude slipping...
How CNBC Cures Is Bringing Rare Disease Stories to a National Audience
CNBC Cures, launched on Jan 8, 2026 by "Squawk Box" co‑host Becky Quick, is the network’s dedicated platform for rare‑disease awareness. Within two months it has produced a weekly newsletter, a podcast series, a live summit, and a prime‑time documentary titled “CNBC...
Why Novo Nordisk's Ireland Expansion Is Key to Fighting Off Eli Lilly
Novo Nordisk announced a €432 million ($506 million) investment to expand its Athlone, Ireland facility, increasing capacity for oral products such as the newly launched Wegovy pill. The expansion is intended to secure supply outside the United States and help the company...
FDA Chief Warns U.S. Is Losing Ground to China in Early Drug Development, Calls for Faster Trial Approvals
FDA Commissioner Marty Makary warned that the United States is falling behind China in early‑stage drug development, citing slower Phase 1 trial volumes and cumbersome regulatory steps. He identified three primary bottlenecks—hospital contracting, ethical review processes, and the IND application workflow—that...
French Prosecutors Are Investigating Companies Like Nestle and Danone over Contaminated Baby Formula. Here's the Latest
French prosecutors have launched investigations into five companies, including Nestlé and Danone, over allegations of contaminated baby formula. The probe follows reports of bacterial presence in products sold across Europe, prompting health warnings and product recalls. Authorities are examining supply...